Guideline Atlas

Ventricular tachycardia

Also known as: sudden cardiac death prevention · ventricular arrhythmia · VT

Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.

United StatesACC/AHA
Current

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death

AHA/ACC/HRS · 2017

Ventricular tachycardia in adults is covered by this broader US guideline on ventricular arrhythmias and sudden cardiac death prevention, which addresses evaluation, acute and chronic management, catheter ablation, antiarrhythmic drug therapy and implantable cardioverter-defibrillator indications across the underlying diseases and syndromes that predispose to VT. It remains the current US document as of 2026. Metadata record only.

  • Issued in 2017 by the American Heart Association, American College of Cardiology and Heart Rhythm Society. source
  • Supersedes the 2006 ACC/AHA/ESC guideline on ventricular arrhythmias and sudden cardiac death. source
  • Covers adults with ventricular arrhythmias or at risk of sudden cardiac death, including indications for implantable cardioverter-defibrillators. source
EuropeESC
Current

2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

European Society of Cardiology (ESC) · 2022

The European guidance on ventricular tachycardia sits inside this broader 2022 ESC guideline on ventricular arrhythmias and sudden cardiac death prevention. It covers diagnostic evaluation, risk stratification, genetic and imaging assessment, and therapeutic strategies including ablation, drugs and defibrillator therapy, across ischaemic and non-ischaemic substrates. Metadata record only.

  • Published in the European Heart Journal in October 2022 and endorsed by the Association for European Paediatric and Congenital Cardiology. source
  • Updates the 2015 ESC guideline on the same topic. source
  • Revision was driven by new evidence on genetics, imaging and clinical risk stratification, plus advances in diagnostic and therapeutic strategies. source

US vs EU key differences

What changed recently

  1. EU201520222022-08-26

    Updating the 2015 ESC guideline, the 2022 version gives catheter ablation a larger role, including in patients without structural heart disease and in stable coronary disease with only mildly reduced ejection fraction, and moves risk stratification beyond ejection fraction alone by adopting disease-specific risk calculators for laminopathy and long QT syndrome alongside the existing hypertrophic cardiomyopathy score.

    source ↗curation confidence 90%
  2. US200620172017-10-30

    The 2017 guideline replaces the 2006 ACC/AHA/ESC ventricular arrhythmia guideline, and also supersedes the ICD indication sections of the 2008 device-based therapy guideline and updates the sudden-death prevention advice in the 2011 hypertrophic cardiomyopathy guideline, consolidating ventricular arrhythmia and sudden cardiac death management in one document.

    source ↗curation confidence 90%

See the full update feed for changes across every system.